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ABSTRACT: Compounds 13 and 14 were evaluated against eleven PARP isoforms to reveal that both 13 and 14 were more potent 
and isoform-selective towards inhibiting tankyrases (TNKSs) than the “standard” inhibitor 1 (XAV939)5, i.e. IC50 = 100 pM vs. 
TNKS2 and IC50 = 6.5 µM vs. PARP1 for 14. In cellular assays, 13 and 14 inhibited Wnt-signaling, enhanced insulin-stimulated 
glucose uptake and inhibited the proliferation of DLD-1 colorectal adenocarcinoma cells to a greater extent than 1. 
INTRODUCTION  
Tankyrases (TNKSs) are members of the poly(ADP-ribose)-
polymerase (PARP) family of seventeen enzymes that use 
NAD+ as a substrate to transfer ADP-ribose units to target pro-
teins.1 There are two human isoforms, TNKS1 and TNKS2. 
Target proteins include telomere repeating binding factor-1 
(TRF1), 2,3 nuclear mitotic apparatus protein (NuMA)4 (essen-
tial for the resolution of chromatids during mitosis) and axin, 
the limiting component of Wnt / -catenin signaling.5 Increased 
Wnt signaling correlates with the overexpression of TNKSs in 
several human cancers.6-9 Inhibition of TNKSs is reported to 
lead to stabilization of axin and decreased nuclear -catenin-
driven proliferation of cancer cells.10 Epidemiological studies 
show that patients with Type-2 diabetes are at higher risk of de-
veloping site-specific cancers11 but the precise mechanisms that 
link diabetes to cancer remain unclear. The axin-TNKS-KIF3A 
complex is required for insulin-stimulated translocation of 
GLUT4 to the cell memembrane.12 Insulin-regulated amino-
peptidase (IRAP) is also a binding partner and target protein of 
TNKSs.13 Together, IRAP and TNKSs can enhance insulin-
stimulated exocytosis of GLUT4, which could result in in-
creased uptake of glucose.13 TNKS-knockout mice display in-
creased sensitivity to insulin and reduced adiposity and pan-
PARP inhibitors have been used to investigate the role of 
TNKSs in studies on the translocation of GLUT4.14 Inhibitor 1 
(XAV939)5  (Fig. 1) has been extensively used as a tool to in-
hibit TNKSs and of Wnt / -catenin signaling5 but lacks the re-
quired isoform-selectivity to avoid off-target effects. Related 
inhibitors of TNKSs include flavones,15 2-arylquinazolin-4-
ones such as 2,16,17 isoquinolin-1-ones18 and aryltetrahydro-
naphthyridinones, which maintain a classical binding mode in 
the nicotinamide-binding site.19 Compound 3 (IWR-1)20 (Fig. 1) 
is an inhibitor of the Wnt signaling cascade through inhibiting 
TNKSs, binding only to the adenosine-binding site.20 The nor-
bornane of 3 forces a conformational change of Tyr1050 (TNKS2 
numbering), allowing the quinoline of 3 to -stack with His1048 
within this site.21 Our previous reports of novel inhibitors in-
clude 2-aryl-8-methylquinazolin-4-ones with 4’-large or elec-
tron-withdrawing substituents (e.g. 2) to provide inhibition of 
TNKSs (IC50 in the low nM range) and of Wnt / -catenin sig-
naling.16,17 Some known inhibitors bind in both the nicotina-
mide-binding site and the adenosine-binding domain,22,23 alt-
hough the increases in potency vs. 1 were modest. 
 
 
 
 
 
 
 
 
Figure 1. Examples of previously studied inhibitors of TNKSs 1, 2 
(nicotinamide-site binders) and 3 (adenosine-site binder). Inhibitor 
2 is shown with locant numbers.  
Here, we report the rational design and evaluation of advanced 
inhibitors (13, 14) which maintain the 8-methylquinazolin-4-
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one core and carry extensions at the 2-position to induce con-
formational change and binding to the adenosine-binding site, 
leading to a step-change in potency and isoform-selectivity. 
These highly potent and isoform-selective inhibitors have po-
tential as excellent molecular probes applicable to research on 
diabetes and cancer. 
 
RESULTS AND DISCUSSION 
Modeling. Structural alignment of the co-crystal structures of 2 
(PDB 4UFU) and 3 (PDB 3UA9) with TNKS217,21 provided in-
itial insights towards the design of 13 and 14. The quinazoli-
none of 2 binds in the nicotinamide-binding site, making the 
expected H-bonds with Ser1068 and Gly1032 and -stack with 
Tyr1071 (TNKS2 numbering). The quinoline of 3 is located in 
the adenosine-binding site, making a -stack with His1048 
(TNKS2 numbering). Features binding at each site were linked 
to create chimeric compounds 13 and 14, which combine im-
portant H-bonds and stacking interactions at both binding sites. 
Modeling of 13 and 14 into the active site of TNKS1 (PDB 
4I9I)23 predicted that the designed compounds could bind to the 
pockets in the intended way and that the length and nature of 
the linker were appropriate (Fig. 2). The quinazolin-4-one core 
could bind in the nicotinamide-binding site to make the classi-
cal H-bond and -stacking interactions. Compounds 1 and 2 
contain a 2-aryl group, which is shown to occupy a hydrophobic 
cavity. Modeling of 13 into TNKS1 suggests that the chosen 
linker could allow Tyr1203 to move towards the nicotinamide-
binding site and decrease the volume of the hydrophobic cavity. 
However, this shrinkage of the pocket could still allow the pro-
panamide linker to thread through. The modeling study reveals 
that the linker could interact further with the protein, in that the 
C=O of the propanamide linker is appositely located to H-bond 
with the backbone NH of Tyr1213. Moreover, the central benzene 
ring and the quinoline of 13 are predicted to cause movement 
of His1201 of the adenosine-binding site to place its imidazole 
appropriately for -stacking with the quinoline. We have previ-
ously reported that an 8-Me group enhances inhibitory activity 
in the simple 2-arylquinazolinones16,17 and related 3-aryli-
soquinolinones,18 we also incorporated the 8-Me in 14, to test if 
it would still make a contribution in these advanced dual-site-
binding compounds (Fig. 2). 
 
 
 
 
 
 
 
 
 
Figure 2. Model of 13 docked into the structure of TNKS1 (PDB 
code 4I9I).23 The protein is shown in pink and 13 in cyan. Key H-
bonds shown as grey dashed lines. 
Chemical Synthesis. The synthesis of target compounds (Sch. 
1) began by acylation of 8-aminoquinoline 4 with 4-nitrobenz-
oyl chloride to give 5, followed by transfer hydrogenation to 
provide amine 6. Anthranilamides 7 and 824 were acylated with 
ethyl 4-chloro-4-oxobutanoate to provide 9 and 10. One-pot cy-
clisation and hydrolysis in aqueous base led to the quinazoli-
nonepropanoic acids 11 and 12. Careful optimization of the 
coupling conditions was required to join 11 / 12 with 6; simul-
taneous addition of the activating agent (CDI) and quinazoli-
nones 11 / 12 to 6 was essential to provide the candidate dual-
site-binding inhibitors 13 and 14 in modest yields.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Synthesis of 13 and 14. Reagents and conditions: i) 
nitrobenzoyl chloride, pyridine, THF, 16 h, Ar; ii) +NH4 HCO2
-
, 10% Pd/C, DMF/MeOH (2:1), 2 h, Ar; iii) 
EtO2CCH2CH2COCl, pyridine, THF, 16 h; iv) aq. NaOH (0.5 
M), 60°C; v) 6, DMF, Pri2NEt, carbonyldiimidazole, 72 h, Ar.   
Biochemical evaluation. The target compounds 13 and 14 
were evaluated in vitro for inhibition of TNKS1 and TNKS2 
and counterscreened against eleven PARP isoforms, including 
the major isoform PARP1 (Table 1). Known inhibitors 1 and 3 
were also examined as standards against PARP1, PARP2, 
TNKS1 and TNKS2. The nicotinamide-site binder 1 showed 
IC50 values in the low nanomolar range for inhibition of TNKS1 
and TNKS2, which were similar to those reported by Huang et 
al.5 However, although 1 showed reasonable selectivity for 
TNKS2 vs. PARP1 (131-fold), other comparisons called into 
question the use of this agent as a selective inhibitor (TNKS1 
vs. PARP1 25-fold; TNKS1 vs. PARP2 4.1-fold). Compound 3, 
which binds in the adenosine-binding site, had moderate activ-
ity against TNKS1 and TNKS2 (IC50 = 343 nM and 31 nM, re-
spectively) and did not inhibit PARP1 or PARP2 up to 10 M. 
These data are again consistent with earlier evaluations of the 
selectivity of this agent. Huang et al.5 reported IC50 (TNKS2) = 
56 nM and selectivity vs. PARP1 and PARP2 > 300-fold, while 
Narwal et al. confirmed the selectivity of 3 with IC50 = ca. 100 
µM (PARP1) and IC50 = ca. 35 µM (PARP2).
21 Thus binding at 
the adenosine site has potential for greater selectivity for 
TNKSs vs. other PARPs, although this may not give high po-
tency as the sole binding site. 
Intermediate 6, containing the putative adenosine-site-binding 
benzamidoquinoline, was evaluated for ability to bind in the ab-
sence of the anchoring quinazolin-4-one but it failed to inhibit 
any of the isoforms. This shows that the norbornane of 3 is es-
sential, interacting with Tyr1203 to modify the geometry of the 
adenosine-binding site to accept the benzamidoquinoline. 
The candidate dual-site inhibitors 13 and 14 were shown to be 
extremely potent and isoform-selective inhibitors of TNKSs, in-
hibiting TNKS2 in the pM range and thus they are both 
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Table 1. IC50 (pIC50 ± standard error) values for inhibition of TNKS1, TNKS2 and PARP isoforms in biochemical assays and for 
inhibition of Wnt signaling in a cellular assay. 
considerably more potent than the “standard” inhibitor 1 and the 
adenosine-site-binder 3. This increase in potency of inhibition 
of the TNKSs for 13 and 14 was not accompanied by an in-
crease in activity against other members of the PARP family 
(Table 1). In particular, 13 and 14 showed very weak activity 
against PARP1 and PARP2 (IC50 >> 6 M), leading to exquisite 
isoform-selectivity. Inhibitor 13 is 4.1  104-fold selective for 
TNKS2 vs. PARP1 and 3.5  104-fold selective for TNKS2 vs. 
PARP2. Similarly, 14 is 6.5  104-fold selective for TNKS2 vs. 
PARP1 and 11.6  104-fold selective for TNKS2 vs. PARP2. 
The somewhat weaker potency of these agents against TNKS1 
corresponds to selectivities for TNKS1 vs. PARP1 and PARP2 
in the range 1-2.3  103-fold. Thus exploiting dual-site binding 
with an appropriate linker makes a step-change in potency and 
provides isoform-selectivity with this potency. Compound 14 is 
approximately twice as potent as 13 against both isoforms, con-
firming the moderate advantage of the 8-Me on the quinazoli-
none core.16,18,17 Intermediates 11 and 12, carrying only a pro-
panoic acid at the quinazolinone 2-position, were evaluated to 
explore the contribution of the quinazolinone-CH2CH2CO unit 
towards potency and selectivity; both showed no inhibition of 
TNKSs. We have previously shown that a 2-aryl group is re-
quired for potent inhibition of TNKSs; this requirement is 
thereby reinforced for inhibitors that bind only as mimics of 
nicotinamide.16-19 However, 11 and 12 do inhibit PARP1 and 
PARP2. Previously, we showed that polar groups at the 4’-po-
sition of 2-arylquinazolin-4-ones decreased selectivity for 
TNKSs, in that inhibition of PARP1 was enhanced;16-18 there-
fore, the 2-propanoic acid of 11 and 12 is well suited to interact 
with the corresponding region of protein of PARP1 that con-
tains hydrophilic residues. Furthermore, 11 and 12 displayed 
moderately potent and selective inhibition of PARP2 (54- and 
6.9-fold, respectively, vs. PARP1), results which place 11 
amongst the most PARP2-selective agents known.25 Therefore, 
11 and 12 provide a new scaffold towards the development of 
novel PARP2-selective inhibitors. 
X-ray crystallography. To rationalize the potency and iso-
form-selectivity of 13 and 14, crystal structures of the com-
pounds in complex with TNKS2 catalytic domain were solved 
(Supplementary information). The quinazolinone binds to the 
nicotinamide pocket as designed and forms interactions with the 
protein similar to those of 2 (PDB code 4UFU).17 The stacking 
interaction with Tyr1071 and the H-bonds with Gly1032 and Ser1068 
are preserved (Fig. 3). Binding of 3 causes opening of the ac-
tive-site loop and moves His1048 away from the binding 
pocket.21 Similar changes are observed in the crystal structures 
of the complexes of 13 and 14 and the quinoline binds to form 
an induced adenosine-binding pocket. Importantly, the H-bonds 
to Tyr1060 and to Asp1045, observed in adenosine-site inhibitors,26 
are both present in the TNKS2 structures containing 13 and 14. 
The central phenyl ring adopts slightly different conformations 
in the experimental crystal structures of 13 and 14, indicating 
flexibility in the hydrophobic surface at this site. A recent dual-
site binding inhibitor binds to the catalytic domain in a very 
similar manner (IC50 = 2 nM vs. TNKS2)
23 but does not create 
as efficient π-stacking interaction with His1201 as does the elec-
tron-poor bicycle of 13 and 14. This may explain why com-
pounds 13 and 14 exhibit such high inhibitory activity towards 
TNKSs. Unlike PARP1 and PARP2, TNKSs do not contain an 
-helical regulatory domain. This domain packs against the 
NAD+-binding groove and the interactions at the adenosine site 
contribute to the potent selectivity of the adenosine-site binders. 
The extreme isoform-selectivity of 13 and 14 can be rational-
ized, similarly to 3, to be mainly due to the quinoline in the 
adenosine-binding pocket and unfavorable interactions with the 
charged residues present in PARP-1 and PARP-2.17,21 
 
 
 
 
 
 
 
 
Compound 1 3 6 11 12 13 14 
PARP1 854 nM  
(6.07 ± 0.13)  
>100000 nM a >100000 nM  a 6700 nM 
 (5.18 ± 0.17) 
1000 nM  
(5.18 ± 0.17) 
8230 nM 
 (5.08 ± 0.12) 
6500 nM 
 (5.19 ± 0.06) 
PARP2 141 nM  
(6.85 ± 0.08) 
>100000 nM a b 125 nM  
(6.90 ± 0.04) 
145 nM  
(6.84 ± 0.12) 
6900 nM 
 (5.16 ± 0.12) 
11600 nM 
(4.94 ± 0.05) 
PARP3      40000 nM 
(4.40 ± 0.14) 
45000 nM 
(4.34 ± 0.10) 
PARP4      69000 nM 
(4.16 ± 0.10) 
65000 nM 
(4.19 ± 0.07) 
TNKS1 34 nM  
(7.47 ± 0.23) 
343 nM  
(6.46 ± 0.09) 
>100000 nM  a >100000 nM a >100000 nM a 9.1 nM  
(8.04 ± 0.05) 
5.1 nM  
(8.29 ± 0.27) 
TNKS2 6.5 nM  
(8.19 ± 0.09) 
31 nM  
(7.51 ± 0.10) 
>100000 nM  a >100000 nM a >100000 nM a 0.20 nM  
(9.69 ± 0.17) 
0.10 nM  
(10.0 ± 0.05) 
PARP10      >100000 nM a >100000 nM a 
PARP12      >100000 nM a >100000 nM a 
PARP14      >100000 nM a >100000 nM a 
PARP15      >100000 nM a >100000 nM a 
PARP16      >100000 nM a >100000 nM a 
Wnt 220nM  
(6.66 ± 0.10)  
136 nMc    29 nM  
(7.54 ± 0.05) 
37 nM  
(7.43 ± 0.06) 
a Limited by solubility. b Empty cells indicate not determined. c Determined previously.23 
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Figure 3. Crystal structure of A) TNKS2-13 (PDB code 5FPF) and 
B) TNKS2-14 (PDB code 5FPG). Hydrogen bonds are shown in 
dashed lines and the electron density (2mFo-DFc) is contoured at 1 
Å around the ligand. 
Inhibition of Wnt signaling in TCF/LEF reporter-HEK293 
cells. The intracellular activity and potency of 13 and 14 was 
evaluated in a functional assay using a TCF/LEF Reporter-
HEK293 cell line (BPS Bioscience, catalog #60501).27 Upon 
extracellular Wnt signals, -catenin is stabilized and associates 
with TCF/LEF transcription factors, activating transcription.5,27 
TNKSs control the stability of the -catenin destruction com-
plex and inhibition is expected to stabilize the destruction com-
plex and thus lower the levels of β-catenin.5 The TCF/LEF Re-
porter-HEK293 cell line is used to measure this interference 
with this pathway. Both 13 (IC50 = 29 nM) and 14 (IC50 = 37 
nM) were shown to be extremely effective and potent cellular 
inhibitors of Wnt / -catenin signaling, confirming their uptake 
into cells and their activity therein (Table 1). Thus 13 and 14 
are ca. 10 more potent in cells than the standard inhibitor 1, 
reflecting the greater potency of the dual-site inhibitors in vitro. 
Cell viability was monitored with a light microscope; 13 and 14 
were not cytotoxic in this assay. 
Anti-proliferative activity towards DLD-1 human colon car-
cinoma cells. Aberrant Wnt signaling is found in > 90% of col-
orectal cancers, owing to mutation in the APC protein which is 
a component of the β-catenin destruction complex.6 Compound 
1 has been reported to have anti-proliferative activity against 
DLD-1 human colon cancer cells but only under serum-de-
prived conditions.5,28 Using a colony-forming assay, 13 and 14 
were shown to inhibit formation of colonies of DLD-1 cells 
even under normal-serum conditions (Fig. 4) at 100 nM and 1.0 
M, conditions under which 1 was inactive. This observation 
again reflects the greater potency of 13 and 14 in vitro and in 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Upper: Exemplary image of DLD-1 colony forming assay 
(1000 cells/well) with 1, 3, 13 and 14 (0 M (control with 1% 
DMSO v/v only), 1.0 M and 100 nM). Lower: Histogram of data 
from assay. 1, 3, 13 and 14 (n = 3). 
Insulin-stimulated glucose uptake. The axin-TNKS-KIF3A 
complex is stabilized through inhibition of TNKS.12 Ablation of 
expression of TNKSs has been reported to upregulate GLUT4 
at the post-transcriptional level, potentially increasing uptake of 
glucose into adipocytes.14 To address this pharmacologically, 
13 and 14 were examined for their ability to enhance insulin-
stimulated uptake of glucose. 3T3-L1 Adipocytes were treated 
with 13 and 14 in the presence of insulin (100 nM).29 Compound 
1 was used for comparison as the current “standard” TNKS in-
hibitor. The insulin-stimulated uptake of radiolabeled 2-deoxy-
D-glucose into the cells was measured. The weaker TNKS in-
hibitor 1 had no effect on insulin-stimulated glucose uptake in 
comparison to the insulin-only control. The slight decrease in 
non-stimulated glucose uptake in presence of 1 (1.0 M) was 
not significantly different from control. Non-stimulated glucose 
uptake in presence of 13 and 14 (1.0 M) was not significantly 
different from control. In comparison to insulin only and with 
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1, both 13 and 14 significantly further increased insulin-stimu-
lated glucose uptake. Glucose uptake increased by ca. 40% and 
20% using 100 nM and 1.0 µM of 13, respectively. Insulin-
stimulated uptake of glucose increased by ca. 20% by 14 at 100 
nM and 1.0 µM in comparison to insulin treatment only (Fig. 
5). This confirms potent intracellular activity of 13 and 14. 
 
 
 
Figure 5. Effect of 1, 13 and 14 on % insulin-stimulated glucose 
uptake in 3T3-L1 adipocytes. Basal levels (B) with or without com-
pound contain no insulin (I). I (with and without compound) ad-
ministered at final concentration 100 nM. Results are mean and 
SEM relative to I only (n = 3 for 1 and n = 5 for 13 and 14). I + 100 
nM 13 vs. I p = 0.02; I + 1.0 M 13 vs. I p = 0.02; I + 100 nM 14 
vs. I p = 0.07; I + 1.0 M 14 vs. I p = 0.01; B vs. B + 13 p = 0.98; 
B vs. B + 14 p = 0.94; B vs. B + 1 p = 0.21. 
 
CONCLUSION 
In this paper, we disclose the design, synthesis and evaluation 
of two new highly potent and isoform-selective TNKS inhibi-
tors, 13 and 14. Crystal structures of these compounds bound 
into the catalytic domain of TNKS2 confirmed that, as de-
signed, the quinazolin-4-one moiety occupied the nicotinamide-
binding site, setting up the linker so that the quinoline moiety 
interacts with the adenosine-binding region. This dual-site de-
sign has led to the most potent and isoform-selective inhibitors 
reported to date, with IC50 = 100 pM for inhibition of TNKS2 
by 14 and 1.2  105-fold selectivity for inhibition of TNKS2 vs. 
the major PARP isoform, PARP1. Cellular uptake of these 
agents was demonstrated by their potent inhibition of Wnt / -
catenin signaling in the low nM range. Significant anti-prolifer-
ative activity was demonstrated in DLD-1 human colon carci-
noma cells at 100 nM under normal serum conditions. For the 
first time, truly potent and selective TNKS inhibitors are shown 
to increase insulin-stimulated glucose uptake, whereas previous 
studies have used non-selective pan-PARP inhibitors;13 this 
provides further evidence of a role of TNKSs in insulin-stimu-
lated glucose transport and further studies will elucidate the 
mechanisms of this activation, presumably through the axin-
TNKS-KIF3A complex.12 In comparative studies in vitro, the 
widely-used TNKS inhibitor 1 has been shown to be markedly 
less potent than 13 and 14 and to lack the exquisite isoform-
selectivity of these new agents. The improved potency and iso-
form-selectivity of 13 and 14 is manifest in three comparative 
cellular functional assays, where they show useful activity in 
situations where 1 lacks potency or activity. 
Compounds 13 and 14 are now available as potent and isoform-
selective TNKS inhibitors which inhibit the Wnt response phar-
macologically in cells. They will have applications as molecular 
tools in studies on Wnt and related systems. These results also 
indicate that inhibition of TNKSs can increase sensitivity of 
cells to insulin, with potential application in Type-2 diabetes, as 
high doses of insulin can cause dysregulation of various signal-
ing cascades (PI3K / Akt / mTOR).30 Antiproliferative activity 
has also been demonstrated in human colon cancer cells under 
normal serum conditions, supporting TNKS as a therapeutic tar-
get in the many cancers with aberrant Wnt signaling. A new 
structural scaffold (11, 12) for selective inhibitors of PARP2 
has also been identified.  
EXPERIMENTAL SECTION 
Chemistry 
The purity of target compounds were >95% as determined by 
1H and 13C NMR, high resolution mass spectrometry using elec-
trospray ionization and HPLC analysis at two different wave-
lengths (see supplementary information for general experi-
mental, spectra of all compounds and synthetic procedures of 
intermediate compounds). 
Synthesis of target compounds 13 and 14. 
2-(3-Oxo-3-(4-((quinolin-8-yl)aminocarbonyl)phenyla-
mino)propyl)quinazolin-4-one (13). Compound 6 (548 mg, 
2.08 mmol) in dry DMF (50 mL) was treated with Pri2NEt (2.96 
g, 22.9 mmol), then carbonyldiimidazole (371 mg, 2.29 mmol), 
followed by addition of 11 (500 mg, 2.29 mmol). The mixture 
was stirred for 72 h under Ar. The solvent was evaporated and 
the residue was dissolved in EtOAc/MeOH (1:2, 70 mL). The 
organic solution was washed with water (3  30 mL) and brine 
(3  30 mL), then dried. Evaporation and chromatography (1:9 
EtOAc / CH2Cl2 → 1:9 MeOH / EtOAc) gave a mixture con-
taining 13. Further chromatography (EtOAc) gave 13 (74 mg, 
8%) as a pale purple solid: mp 265-268°C 1H NMR ((CD3)2SO) 
2.95-2.98 (4 H, m), 7.47 (1 H, t, J = 7.0 Hz), 7.63 (1 H, d, J = 
8.0 Hz), 7.64-7.69 (2 H, m), 7.72-7.83 (2 H, m), 7.82 (2 H, d, J 
= 8.5 Hz), 8.00 (2 H, d, J = 8.5 Hz), 8.08 (1 H, d, J = 8.0 Hz), 
8.46 (1 H, dd, J = 8.0, 1.5 Hz), 8.72 (1 H, d, J = 7.5 Hz), 8.97 
(1 H, dd, J = 4.0, 1.5 Hz), 10.45 (1 H, s), 10.59 (1 H, s), 12.27 
(1 H, s); 13C NMR ((CD3)2SO) 29.09, 32.34, 116.44, 118.70, 
120.93, 122.13, 122.38, 125.77, 126.04, 126.76, 127.11, 
127.86, 128.12, 128.44, 134.16, 134.35, 136.81, 138.26, 
142.76, 148.74, 149.18, 156.52, 161.64, 163.96, 170.73; MS 
m/z 464.1722 [M + H]+ (C27H22N5O3 requires 464.1723). 
8-Methyl-2-(3-oxo-3-(4-((quinolin-8-yl)aminocarbonyl)phe-
nylamino)propyl)quinazolin-4-one (14). Compound 6 (514 
mg, 1.95 mmol) in dry DMF (50 mL) was treated with Pri2NEt 
(2.78 g, 21.5 mmol), then carbonyldiimidazole (348 mg, 2.15 
mmol), followed by addition of 12 (500 mg, 2.15 mmol). The 
mixture was stirred for 72 h under Ar. The solvent was evapo-
rated and the residue was dissolved in EtOAc/MeOH (1:2, 70 
mL). The solution was washed with water (3  30 mL) and brine 
(3  30 mL), then dried. Evaporation and chromatography (1:9 
EtOAc / CH2Cl2 → EtOAc) gave 14 (119 mg, 21%) as a beige 
solid: mp 280-282°C; 1H NMR ((CD3)2SO)  2.44 (3H, s), 2.93 
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(2 H, t, J = 6.0 Hz), 3.01 (2 H, t, J = 7.0 Hz), 7.31 (1 H, t, J = 
7.5 Hz), 7.58 (1 H, m), 7.63-7.69 (2 H, m), 7.70 (1 H, dd, J = 
8.5, 1.0 Hz), 7.83 (2 H, d, J = 8.5 Hz), 7.91 (1 H, dd, J = 8.0, 
1.0 Hz), 8.00 (2 H, d, J = 8.5 Hz), 8.46 (1 H, dd, J = 8.5, 2.0 
Hz), 8.72 (1 H, dd, J = 7.5, 1.5 Hz), 8.97 (1 H, dd, J = 4.5, 2.0 
Hz), 10.76 (1 H, s), 10.59 (1 H, s), 12.25 (1 H, s); 13C NMR 
((CD3)2SO) 17.06, 28.99, 32.08, 116.45, 118.67, 120.76, 
122.11, 122.38, 123.36, 125.44, 127.11, 127.86, 128.09, 
128.34, 134.17, 134.59, 134.84, 136.81, 138.26, 142.91, 
147.07, 149.17, 155.12, 161.94, 163.98, 170.98; MS m/z 
478.1876 [M + H]+ (C28H24N5O3 requires 478.1879). 
Counter-screening against PARP3, PARP4, PARP10, 
PARP12, PARP14, PARP15 and PARP16. Compounds 13 
and 14 were counter-screened for inhibition of these isoforms 
using methods described previously.31, 32 The new inhibitors 
show no structural alerts for PAINS and are colorless and non-
fluorescent. 
Insulin-stimulated glucose uptake. 3T3-L1 fibroblasts (from 
the American Type Culture Collection), were cultured in 
DMEM and differentiated to adipocytes by treatment with in-
sulin, dexamethasone and isobutylmethylxanthine, as described 
previously.29 On the day of the experiment, 10-12 d post-differ-
entiation, the cells were incubated with serum-free DMEM for 
2 h at 37C. Cells in the treatment group were treated with in-
creasing concentrations of 13 or 14 for 1 h. At the end of the 
incubation period, the cells were washed thrice with Krebs-
Ringer-HEPES (KRH) buffer (140 mM NaCl, 4.7 mM KCl, 2.5 
mM CaCl2, 1.25 mM MgSO4, 2.5 mM NaH2PO4, 10 mM 
HEPES, (pH 7.4)) and incubated for 30 min with 13 or 14 and 
in either the absence or presence of insulin (100 nM) at 37C. 
After the 30 min incubation period, 2-deoxy-D-[2,6-3H]glucose 
(final concentration 50 M, 0.1 Ci well-1) was added for 5 min 
and the cells were washed four times with ice-cold KRH buffer. 
Nonspecific uptake of 2-deoxy-D-glucose was measured in the 
presence of 10 M cytochalasin B. The cells were lysed in aq. 
NaOH (0.1 M) and radioactivity was counted in a TriCarb Pack-
ard scintillation counter (Perkin-Elmer). The concentrations of 
proteins were measured using BCA protein assay kit (Thermo 
Fisher Scientific). Results were calculated as nmol of 2-deoxy-
D-glucose min-1 (mg protein)-1 and are expressed as % of insu-
lin-only control. Statistical analysis; results were analyzed us-
ing two-tailed paired t tests. 
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